SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 2, 2018--
Inc. (Nasdaq: VCYT) today announced that Bonnie Anderson, chairman
and chief executive officer, will speak at the 2018 MedCity
CONVERGE conference in a session entitled, “Early Diagnosis Through
Predictive Biomarkers, Noninvasive Testing,” which will focus on
opportunities to detect cancer at its earliest stages. The session will
be held in Philadelphia on July 11 at 5:00 p.m. Eastern Time.
Ms. Anderson will join fellow executives in a discussion of emerging
technologies and genomic discoveries – and what will be needed to
translate these developments into actionable tests that ultimately
transform how cancer is diagnosed and treated. She will share her
perspectives on critical opportunities in lung cancer, where Veracyte
has a commercialized genomic test that helps improve lung cancer
diagnosis and is pursuing development of a simple nasal swab test to
detect the disease at its earliest stages, when it is more treatable.
“The vast majority of our healthcare resources currently focus on
treating cancer once it is diagnosed, which is often too late,” said Ms.
Anderson. “However, advances in genomic science, sequencing technology
and machine learning are providing tremendous new opportunities to
detect cancer earlier, when it can be treated and potentially even
prevented. This is particularly true in lung cancer, which still kills
more Americans than the next three leading cancers combined.”
MedCity CONVERGE is a two-day conference that gathers executives
representing technology disruptors, payers, providers, life science
companies, venture capitalists and more to discuss how Artificial
Intelligence, Big Data and Precision Medicine are changing the game in
cancer. The 2018 event will take place in Philadelphia on July 11 and
12. More information can be found at https://events.medcitynews.com/converge/.
Veracyte, Inc. (Nasdaq: VCYT) is a leading genomic diagnostics company
that is providing trustworthy and actionable answers that fundamentally
improve patient care when current diagnostic tests are uncertain. The
company's products uniquely combine genomic technology, clinical science
and machine learning to provide answers that give physicians and
patients a clear path forward without risky, costly surgery that is
often unnecessary. Since its founding in 2008, Veracyte has
commercialized three genomic tests, which are transforming the diagnosis
of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and
collectively target a $2 billion market opportunity. Veracyte is based
in South San Francisco, California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma
logo are trademarks of Veracyte, Inc.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "expect," "believe," "should," "may,"
"will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that we
have a strong foundation in place to drive revenue growth, our beliefs
regarding momentum in our business and potential drivers of future
growth, our expectations regarding full-year 2018 revenue and cash burn,
our introduction of our Afirma Xpression Atlas platform, our
expectations regarding our ability to receive Medicare reimbursement and
expand commercialization of our Envisia Genomic Classifier, our
expectations for the continued expansion in the commercialization of
Percepta and our ability to drive revenue growth across our
endocrinology and pulmonology franchises. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead,
they are based only on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies,
anticipated events and trends, the economy and other future conditions.
Forward-looking statements involve risks and uncertainties, which could
cause actual results to differ materially, and reported results should
not be considered as an indication of future performance. These risks
and uncertainties include, but are not limited to our history of losses
since inception; our ability to enhance the performance of our Afirma
classifier; our ability to successfully transition to our
next-generation Afirma Genomic Sequencing Classifier; the performance
and acceptance of our Percepta and Envisia classifiers; our ability to
increase usage of and reimbursement for the Afirma and Percepta
classifiers and to obtain adequate reimbursement for our Envisia
classifier, as well as any future products we may develop or sell; our
ability to continue our momentum and growth; our dependence on a few
payers for a significant portion of our revenue; and other risks set
forth in the company's filings with the Securities and Exchange
Commission, including the risks set forth in the company's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2018. These
forward-looking statements speak only as of the date hereof and Veracyte
specifically disclaims any obligation to update these forward-looking
View source version on businesswire.com: https://www.businesswire.com/news/home/20180702005294/en/
Source: Veracyte, Inc.
Tracy Morris, 650-380-4413